Vermont Public is independent, community-supported media, serving Vermont with trusted, relevant and essential information. We share stories that bring people together, from every corner of our region. New to Vermont Public? Start here.

© 2025 Vermont Public | 365 Troy Ave. Colchester, VT 05446

Public Files:
WVTI · WOXM · WVBA · WVNK · WVTQ
WVPR · WRVT · WOXR · WNCH · WVPA
WVPS · WVXR · WETK · WVTB · WVER
WVER-FM · WVLR-FM · WBTN-FM

For assistance accessing our public files, please contact hello@vermontpublic.org or call 802-655-9451.
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations

Sen. Welch hopes Trump will rally support for prescription drug cost bill

A man gestures while speaking
Ben Curtis
/
Associated Press
Sen. Peter Welch, pictured at the Senate Finance Committee confirmation hearing for Scott Bessent on Thursday, Jan. 16, is sponsoring a bill with Republican Sen. Josh Hawley that would prohibit pharmaceutical companies from selling drugs in the U.S. at prices higher than the international average.

Sen. Peter Welch is encouraging President Donald Trump to take an active role to help pass legislation that would significantly lower the cost of many prescription drugs.

Recently, the president issued an executive order that mirrors the language of a bipartisan bill sponsored by Welch.

The legislation prohibits pharmaceutical companies from selling drugs in this country at a price higher than the international average.

More from NPR: Trump signs an order to reduce drug prices, but it's unclear how it would work

Welch said the president could play a key role in persuading Republican members of Congress to support the bill.

"They need aggression on the part of the president to really step up," Welch said. "But I think the president understands that America is getting ripped off — and he always wants, quote, 'a good deal.'"

Welch said the bill would have a huge impact on consumers in this country, because many of the drugs are available in Canada and Europe at much lower prices.

"Why should the U.S. pay more for the same drug — two, three, four, five times more than what they pay in Europe and Canada — particularly when U.S. taxpayers really funded a lot of the research?" Welch said.

Opponents of the proposal argue it will stifle important research conducted by pharmaceutical companies.

Bob Kinzel has been covering the Vermont Statehouse since 1981 — longer than any continuously serving member of the Legislature. With his wealth of institutional knowledge, he answers your questions on our series, "Ask Bob."

Have questions, comments or tips? Send us a message.

Loading...


Latest Stories